|Bid||0.4305 x 800|
|Ask||0.4600 x 1200|
|Day's Range||0.4424 - 0.4725|
|52 Week Range||0.4000 - 3.9200|
|Beta (3Y Monthly)||-1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2019 - Nov 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.86|
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors’ process remains underway to evaluate strategic alternatives to maximize shareholder value.
Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.
NEWARK, N.J., July 29, 2019 -- The Rosen Law Firm, P.A. announces that the United States District Court District of New Jersey has approved the following announcement of a.
Akers Biosciences Inc NASDAQ:AKERView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $450 million over the last one-month into ETFs that hold AKER are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three months ended March 31, 2019. At March 31, 2019, Akers Bio had cash, restricted cash and marketable securities of $5.23 million. During the fourth quarter of 2018, the Board of Directors initiated a process to evaluate strategic alternatives to maximize shareholder value.
South Jersey medical device maker Akers Biosciences Inc. — which saw its sales cut in half last year — said it is continuing to evaluate 'strategic alternatives" that include looking at business combinations in alternative sectors such as cannabis related industries. “Our focus throughout the latter part of 2018 and into 2019 has been on streamlining the company’s operations, rightsizing human resources with a concentration on products which currently generate sales, cutting unnecessary corporate expense and resolving legacy issues," said Howard R. Yeaton, CEO and interim-CFO at Akers BioSciences (NASDAQ: AKER).
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the fiscal year ended December 31, 2018. At December 31, 2018, Akers Bio had cash, restricted cash and marketable securities of $5.96 million, which the Company reports is sufficient to fund its obligations into 2020. The process is ongoing and will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries.
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.
CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Akers Biosciences, Inc. (NASDAQ: AKER)'s stock was trending on Benzinga Pro Tuesday, with shares of the microcap trading on 40-percent higher than average volume. The stock's decline — it was down 11.7 percent at $1.54 at the time of publication Tuesday — follows the 42.28-percent jump the shares registered Monday following an announcement that the company could enter the cannabis industry. What Is Akers? Akers Biosciences develops and manufactures rapid screening and testing products for health care providers and consumers.
NEW YORK, NY / ACCESSWIRE / November 20, 2018 / While Akers Biosciences shares were exploding on the news that the company is considering the cannabis industry, shares of Align Technology were plummeting on a pessimistic highlight of the company in the Wall Street Journal from over the weekend. Align Technology, Inc. Akers Biosciences, Inc. shares closed up 42.28% on Monday on tremendous trading volume of nearly 15.4 million shares traded.
The Thorofare, N.J., company which began exploring "strategic alternatives" earlier this month has hired a legal advisor to advise it on potential business combinations in the cannabis industry.